{"id":"NCT01368081","sponsor":"Boehringer Ingelheim","briefTitle":"Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus","officialTitle":"A 52-week, Randomised, Multi-centre, Parallel Group Study to Investigate the Safety and Efficacy of BI 10773 (10 mg or 25 mg Administered Orally Once Daily) as add-on Therapy to an Oral Antidiabetic Drug (Sulfonylurea, Biguanide, Thiazolidinedione, Alpha Glucosidase Inhibitor, DPP-IV Inhibitor, or Glinide) in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-05","primaryCompletion":"2013-04","completion":"2013-04","firstPosted":"2011-06-07","resultsPosted":"2014-06-17","lastUpdate":"2014-06-17"},"enrollment":1162,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Metformin","otherNames":[]},{"type":"DRUG","name":"BI 10773","otherNames":[]},{"type":"DRUG","name":"Placebo (low dose)","otherNames":[]},{"type":"DRUG","name":"BI 10773","otherNames":[]},{"type":"DRUG","name":"Placebo (high dose)","otherNames":[]}],"arms":[{"label":"BI 10773 low dose","type":"EXPERIMENTAL"},{"label":"BI 10773 high dose","type":"EXPERIMENTAL"},{"label":"Metformin","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of the study is to investigate the long-term safety and efficacy of BI 10773 given for 52 weeks as add-on therapy to one oral antidiabetic drug in patients with type 2 diabetes mellitus with insufficient glycaemic control.","primaryOutcome":{"measure":"Number of Patients With Drug Related Adverse Events","timeFrame":"After the first drug intake until 7 days after the last treatment administration, up to 383 days","effectByArm":[{"arm":"Sulfonylurea: Empa 10mg","deltaMin":19,"sd":null},{"arm":"Sulfonylurea: Empa 25mg","deltaMin":25,"sd":null},{"arm":"Sulfonylurea: Metformin","deltaMin":13,"sd":null},{"arm":"Biguanide: Empa 10mg","deltaMin":13,"sd":null},{"arm":"Biguanide: Empa 25mg","deltaMin":9,"sd":null},{"arm":"Thiazolidinedione: Empa 10mg","deltaMin":20,"sd":null},{"arm":"Thiazolidinedione: Empa 25mg","deltaMin":19,"sd":null},{"arm":"Alpha Glucosidase Inhibitor: Empa 10mg","deltaMin":7,"sd":null},{"arm":"Alpha Glucosidase Inhibitor: Empa 25mg","deltaMin":5,"sd":null},{"arm":"DPP-IV Inhibitor: Empa 10mg","deltaMin":9,"sd":null},{"arm":"DPP-IV Inhibitor: Empa 25mg","deltaMin":18,"sd":null},{"arm":"Glinide: Empa 10mg","deltaMin":9,"sd":null},{"arm":"Glinide: Empa 25mg","deltaMin":9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":87,"countries":["Japan"]},"refs":{"pmids":["28753486","25772548"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":136},"commonTop":["Nasopharyngitis","Constipation","Fall","Pollakiuria","Back pain"]}}